13o3
Family officeMelbourne · Seed–Late Stage
Investment thesis
13o3 provides tailored wealth management and asset deployment services, constructing individualized portfolios based on each client's financial goals, investment horizon, risk tolerance, and needs such as tax optimization or estate planning. The firm emphasizes diversification across asset classes, sectors, and regions to preserve capital and drive long-term growth, while offering transparency, active client communication, and inflation-proof strategies. It builds investment funds around high-conviction market themes, attracts institutional capital, and works through a broad partner network to scale strategies.
Source: firm website, verified Aug 3, 2026.
Frequently asked questions
- What stage does 13o3 invest at?
- 13o3 invests at the Seed, Growth, Late Stage stages.
- What is 13o3's typical check size?
- 13o3 typically writes checks of $200K – $1M.
- What sectors does 13o3 focus on?
- 13o3 focuses on Impact & Social Good.
- Where is 13o3 located?
- 13o3 is headquartered in Melbourne, AU.
- Does 13o3 lead rounds?
- 13o3 typically participates in rounds rather than leading them.
Images
Similar investors
500 Global (formerly 500 Startups) is a venture capital firm that invests in startups worldwide and runs programs for founders and investors.
Octopus Ventures is a founder-focused European venture capital firm that backs mission-driven startups across seven core sectors, investing from idea stage through growth with a focus on pre-seed to Series A.
CareQuest Innovation Partners drives innovation in oral and integrated health through impact investing, innovation programs, and corporate partnerships aimed at improving accessibility, equity, and the integration of oral health with overall health.
H/L Ventures is a New York-based venture firm and company-building studio that co-builds startups with founders from idea stage through scale, and provides growth equity and credit capital as companies mature.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.